Sellas Life Sciences Group Inc. (SLS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sellas Life Sciences Group Inc. (SLS:NASDAQ), powered by AI.

Current Price
$7.83
P/E Ratio
-31.8
Market Cap
854M
Sector
Healthcare
What is the Sellas Life Sciences Group Inc. stock price forecast?

Sellas Life Sciences Group Inc. is currently trading at $7.83. View real-time AI analysis on Alpha Lenz.

What is Sellas Life Sciences Group Inc. insider trading activity?

View the latest insider trading data for Sellas Life Sciences Group Inc. on Alpha Lenz.

What is Sellas Life Sciences Group Inc.'s P/E ratio?

Sellas Life Sciences Group Inc.'s P/E ratio is -31.8.

Sellas Life Sciences Group Inc.

NASDAQ · SLS
$7.83+0.08(+1.03%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Sellas Life Sciences Group Inc.'s future dividend policy...
Alpha Chat Insight

Sellas Life Sciences Group Inc. trades at a P/E of -31.8 (undervalued) with modest ROE of -66.9%.

Ask for details

Company Overview

Sellas Life Sciences Group Inc. is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapies. Its chief aim is to address unmet medical needs in oncology by advancing its proprietary platform of innovative targeted treatments. The company's core offerings include proprietary therapies designed to enhance the body’s immune response against various forms of cancer. Sellas is particularly notable for its research into therapies targeting hard-to-treat cancers such as acute myeloid leukemia and ovarian cancer. As it operates in the high-stakes biopharmaceutical sector, Sellas Life Sciences significantly impacts the healthcare industry by pushing the boundaries of possible cancer treatments. By collaborating with research institutions and leveraging cutting-edge technology, Sellas plays a pivotal role in the growing field of precision medicine, advancing treatment options that offer new hope to patients worldwide.

CEODr. Angelos M. Stergiou M.D., ScD h.c.
SectorHealthcare
IndustryBiotechnology
Employees15

Company Statistics

FY 2025

Profile

$853.87MMarket Cap
$0.00Revenue
0.00Shares Out
15Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-31.79P/E
12.05P/B
N/AEV/Sales
-27.70EV/EBITDA
-30.08P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-54.95%ROA
-66.88%ROE
-57.83%ROIC

Financial Health

$71.79MCash & Cash Equivalents
$-64.32MNet Debt
10.55%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sellas Life Sciences Group Inc. (ticker: SLS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15 employees. Market cap is $854M.

The current price is $7.83 with a P/E ratio of -31.79x and P/B of 12.05x.

ROE is -66.88%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sellas Life Sciences Group Inc. (SLS) Stock Forecast 2026 $7.83 — Price, Financials & Analyst Targets | Alpha Lenz